VISITOR Clinical Study Demonstrates Feasibility and Utility of Transparency Life Sciences’ New Virtual Trials Platform

Management Team


Harry Glorikian — Chief Executive Officer

Harry has been the Managing Director of Strategy and Personalized Medicine at Precision for Medicine, Inc. since joining in December 2012. Mr. Glorikian has more than 20 years of experience in the health care and life science industries. He holds a BSBA and MBA from Boston University and a BA in General Biology from San Francisco State University.

Susan Wong, PA — Vice President, Strategic and Clinical Operations

Susan Wong brings over 20 years of industry experience to TLS. She has served in leadership roles in Clinical Operations, Development, Project Management and Compliance. For the past four years, Susan has been developing the strategic and operational aspects of executing decentralized, virtual clinical trials. She has worked in large and small companies, including sites, sponsors and CROs, and therapeutic areas ranging from cardiovascular, neurology, endocrine, and oncology. Throughout her career, Susan has participated in medical mission excursions to remote and underserved areas globally. Susan received her Bachelor of Science degree from UCLA and obtained a Physician Assistant (PA) certification from USC, specializing in emergency medicine.

Julian Mulla — Chief Technology Officer

Mr. Mulla has over 20 years of experience with software development and running technology companies as CTO. In addition he also brings strong machine learning proficiency and big data analytics experience. He is also winner of the 8th Balkan Mathematical Olympiad.

Stuart Barlow, MBA, CPA, CGMA — Chief Financial Officer

Stuart Barlow brings 10 years of senior financial management in drug development to TLS, following his role as Chief Accounting Officer for Auven Therapeutics Holdings LP, an international private equity fund engaged in cancer, ophthalmic, and orphan drug development. Prior to Auven, Mr. Barlow had public and private company controllership responsibilities in the health insurance, consumer packaged goods, and consumer electronics industries. Mr. Barlow holds a BA in political science from Boston University and an MBA in Finance and Accounting from the Columbia University School of Business Administration. He is a CPA licensed in New York State, a Chartered Global Management Accountant, and a member of Financial Executives International.

Board of Directors


Harry Glorikian


Richard Warburg, PhD — Partner, New Ventures III

Richard Warburg has served as a Partner at Auven Therapeutics, and Head of Intellectual Property at ADC Therapeutics. He serves as an Advisor of Gensys Software, Inc. Previously, Dr. Warburg was a Partner at the law firms of Foley & Lardner LLP and Lyon & Lyon. He attended Suffolk University Law School, and is a graduate of Birmingham University, England, where he completed his Ph.D. in Molecular Biology.

Tomasz Sablinski, MD, PhD

Tomasz Sablinski has 35 years of experience in healthcare. This includes 20 years of pharmaceutical development at Novartis, overseeing clinical development projects at Parexel, consulting for biotechnology companies and managing a development portfolio at Auven Therapeutics. In the 1990s Dr. Sablinski was a member of teams at Harvard Medical School (Brigham and Women’s and Massachusetts General Hospitals) conducting pioneering work in developing biologic immunosuppressive regimens, induction of transplantation tolerance and xenotransplantation. He also practiced as a surgeon specializing in renal transplantation and general surgery in his native Poland and in Boston. Dr. Sablinski received his MD and PhD degrees from the Medical University of Warsaw in Poland. Most recently Dr. Sablinski was Managing Director at Auven Therapeutics, a New York City-based private equity fund.

John Dessouki

John joined the New Ventures Team in 2015 after working at Route 66 Ventures, a private equity and venture capital firm focused on credit and equity investments in financial service companies. John holds an MBA from the Darden School of Business at the University of Virginia and a Masters in Accounting from the Mason School of Business at the College of William and Mary.



Patrick O’Connor

Dr. O’Connor is a registered specialist in the U.K., with accreditation in internal medicine and clinical pharmacology. Dr. O’Connor, joined Boots Pharmaceuticals in 1984, serving in a number of positions culminating in his appointment as Vice President Medical Research for Boots Pharmaceuticals in the USA. From 1991 to 2002 he held various senior positions at PPD including Head of Regulatory and Product Development for PPD. In 2002 he was appointed Head of Global Clinical Development at the Ferring Group of Companies. In 2005 he joined Celtic Pharma Development Services as Head of Clinical Development. In 2012 he joined Celtic Therapeutics (Auven Therapeutics) as Managing Director Clinical Strategy. In 2018 he joined Lakewood Amedex an antimicrobial company as chief Medical Officer. He has a range of experience including simple molecules to bispecific antibody drug conjugates, with a particular interest in digital processes to shorten drug development times and reduce costs.


Barbara Lindheim — BLL Partners

​Barbara Lindheim is a founder and managing partner at BLL Partners LLC, a consultancy providing strategic communications services to the biotechnology and life sciences industries. Barbara brings her clients more than two decades of industry experience in strategic positioning, corporate and product communications, investor relations and marketing. Her prior experience includes senior strategy and communications roles at BioCom Partners, Orchid BioSciences, Edelman Worldwide, Noonan/Russo Communications, Glaxo SmithKline, Sanofi predecessor company Sterling Winthrop and Pfizer. A graduate of Cornell University, Barbara earned an MBA with distinction from Harvard Business School and a masters in public policy from Princeton University.

Always stay in the loop.
Sign up for our latest updates.